{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:50:45Z","timestamp":1790495445841,"version":"4.1.0"},"reference-count":151,"publisher":"European Respiratory Society (ERS)","issue":"2","license":[{"start":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:00:00Z","timestamp":1610582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2020,12,14]]},"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:p>\n                    Chronic obstructive pulmonary disease (COPD) is a common and preventable airway disease causing significant worldwide mortality and morbidity. Lifetime exposure to tobacco smoking and environmental particles are the two major risk factors. Over recent decades, COPD has become a growing public health problem with an increase in incidence. COPD is defined by airflow limitation due to airway inflammation and small airway remodelling coupled to parenchymal lung destruction. Most patients exhibit neutrophil-predominant airway inflammation combined with an increase in macrophages and CD8\n                    <jats:sup>+<\/jats:sup>\n                    T-cells. Asthma is a heterogeneous chronic inflammatory airway disease. The most studied subtype is type 2 (T2) high eosinophilic asthma, for which there are an increasing number of biologic agents developed. However, both asthma and COPD are complex and share common pathophysiological mechanisms. They are known as overlapping syndromes as approximately 40% of patients with COPD present an eosinophilic airway inflammation. Several studies suggest a putative role of eosinophilia in lung function decline and COPD exacerbation. Recently, pharmacological agents targeting eosinophilic traits in uncontrolled eosinophilic asthma, especially monoclonal antibodies directed against interleukins (IL-5, IL-4, IL-13) or their receptors, have shown promising results. This review examines data on the rationale for such biological agents and assesses efficacy in T2-endotype COPD patients.\n                  <\/jats:p>","DOI":"10.1183\/23120541.00437-2020","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T13:49:20Z","timestamp":1610632160000},"page":"00437-2020","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":42,"title":["Targeted therapy in eosinophilic chronic obstructive pulmonary disease"],"prefix":"10.1183","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7127-8451","authenticated-orcid":false,"given":"Mathieu","family":"Fieldes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Bourguignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"Assou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amel","family":"Nasri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Fort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Vachier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"De Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Engi","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4645-5209","authenticated-orcid":false,"given":"Arnaud","family":"Bourdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2021,1,14]]},"reference":[{"key":"2024101711012803000_7.2.00437-2020.1","unstructured":"IMHE, Institute for Health Metrics and Evaluation (IHME). GBD Compare. Seattle, WA: IHME, University of Washington, 2015. http:\/\/www.healthdata.org\/data-visualization\/gbd-compare Date last accessed: May, 2020; date last updated: May 2020."},{"key":"2024101711012803000_7.2.00437-2020.2","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-2600(17)30293-X","article-title":"Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"5","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2024101711012803000_7.2.00437-2020.3","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-9-7"},{"key":"2024101711012803000_7.2.00437-2020.4","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.06.00124605"},{"key":"2024101711012803000_7.2.00437-2020.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61377-4"},{"key":"2024101711012803000_7.2.00437-2020.6","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00089607"},{"key":"2024101711012803000_7.2.00437-2020.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67632-5"},{"key":"2024101711012803000_7.2.00437-2020.8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005685"},{"key":"2024101711012803000_7.2.00437-2020.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60879-9"},{"key":"2024101711012803000_7.2.00437-2020.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60990-2"},{"key":"2024101711012803000_7.2.00437-2020.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31222-9"},{"key":"2024101711012803000_7.2.00437-2020.12","doi-asserted-by":"crossref","first-page":"020415","DOI":"10.7189\/jogh.05.020415","article-title":"Global and regional estimates of COPD prevalence: Systematic review and meta-analysis","volume":"5","author":"Adeloye","year":"2015","journal-title":"J Glob Health"},{"key":"2024101711012803000_7.2.00437-2020.13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.284692"},{"key":"2024101711012803000_7.2.00437-2020.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2015.10.012"},{"key":"2024101711012803000_7.2.00437-2020.15","unstructured":"WHO. Projections of mortality and causes of death, 2016 to 2060. www.who.int\/healthinfo\/global_burden_disease\/projections\/en\/ Date last accessed: April 5, 2020; date last updated: April 2020."},{"key":"2024101711012803000_7.2.00437-2020.16","unstructured":"The economic burden of lung disease. In: Gibson GJ, Loddenkemper R, Sibille Y, et al., eds. European Lung White Book. Sheffield, European Respiratory Society, 2013. www.erswhitebook.org\/chapters\/the-economic-burden-of-lung-disease\/"},{"key":"2024101711012803000_7.2.00437-2020.17","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10198-019-01119-1","article-title":"The economic burden of chronic obstructive pulmonary disease (COPD) in Europe: results from a systematic review of the literature","volume":"21","author":"Rehman","year":"2020","journal-title":"Eur J Health Econ"},{"key":"2024101711012803000_7.2.00437-2020.18","first-page":"621","article-title":"Hospitalizations for COPD exacerbations: trends and determinants of death","volume":"12","author":"Molinari","year":"2015","journal-title":"COPD"},{"key":"2024101711012803000_7.2.00437-2020.19","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.rmr.2014.10.731","article-title":"[Management and costs of chronic pulmonary obstructive disease in France in 2011]","volume":"32","author":"Laurendeau","year":"2015","journal-title":"Rev Mal Respir"},{"key":"2024101711012803000_7.2.00437-2020.20","doi-asserted-by":"publisher","DOI":"10.3109\/15412555.2010.481697"},{"key":"2024101711012803000_7.2.00437-2020.21","doi-asserted-by":"publisher","DOI":"10.1378\/chest.118.5.1278"},{"key":"2024101711012803000_7.2.00437-2020.22","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.58.5.388"},{"key":"2024101711012803000_7.2.00437-2020.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713901"},{"key":"2024101711012803000_7.2.00437-2020.24","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01359-2015"},{"key":"2024101711012803000_7.2.00437-2020.25","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. 2020 GOLD Reports - Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. www.goldcopd.org\/gold-reports\/ Date last accessed: 2020; date last updated: 2021."},{"key":"2024101711012803000_7.2.00437-2020.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16900-6"},{"key":"2024101711012803000_7.2.00437-2020.27","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0140-6736(80)90493-6","article-title":"Increased alveolar epithelial permeability in cigarette smokers","volume":"315","author":"Jones","year":"1980","journal-title":"Lancet"},{"key":"2024101711012803000_7.2.00437-2020.28","first-page":"2484","article-title":"Update on the pathogenesis of COPD. Reply","volume":"381","author":"Agust\u00ed","year":"2019","journal-title":"N Engl J Med"},{"key":"2024101711012803000_7.2.00437-2020.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106955"},{"key":"2024101711012803000_7.2.00437-2020.30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61303-9"},{"key":"2024101711012803000_7.2.00437-2020.31","doi-asserted-by":"publisher","DOI":"10.1038\/nature15371"},{"key":"2024101711012803000_7.2.00437-2020.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411532"},{"key":"2024101711012803000_7.2.00437-2020.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1603287"},{"key":"2024101711012803000_7.2.00437-2020.34","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S2213-2600(15)00480-4","article-title":"The complex challenge of chronic obstructive pulmonary disease","volume":"3","author":"Duffy","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2024101711012803000_7.2.00437-2020.35","doi-asserted-by":"publisher","DOI":"10.1038\/ng.571"},{"key":"2024101711012803000_7.2.00437-2020.36","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0342-2"},{"key":"2024101711012803000_7.2.00437-2020.37","doi-asserted-by":"publisher","DOI":"10.1038\/ng.941"},{"key":"2024101711012803000_7.2.00437-2020.38","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3752"},{"key":"2024101711012803000_7.2.00437-2020.39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66781-5"},{"key":"2024101711012803000_7.2.00437-2020.40","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201104-0597OC"},{"key":"2024101711012803000_7.2.00437-2020.41","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2147\/COPD.S155306","article-title":"Targeting IL-5 in COPD","volume":"14","author":"Narendra","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2024101711012803000_7.2.00437-2020.42","doi-asserted-by":"publisher","DOI":"10.1042\/CS20160487"},{"key":"2024101711012803000_7.2.00437-2020.43","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0010-2019"},{"key":"2024101711012803000_7.2.00437-2020.44","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1155\/2011\/430317","article-title":"Heterogeneity of bronchitis in airway diseases in tertiary care clinical practice","volume":"18","author":"D'silva","year":"2011","journal-title":"Can Respir J"},{"key":"2024101711012803000_7.2.00437-2020.45","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/15412555.2018.1437897","article-title":"Biologic drugs: a new target therapy in COPD?","volume":"15","author":"Yousuf","year":"2018","journal-title":"COPD"},{"key":"2024101711012803000_7.2.00437-2020.46","doi-asserted-by":"crossref","first-page":"e12674","DOI":"10.1111\/sji.12674","article-title":"The role of Th1\/Th2 cytokines played in regulation of specific CD4+ Th1 cell conversion and activation during inflammatory reaction of chronic obstructive pulmonary disease","volume":"88","author":"Sun","year":"2018","journal-title":"Scand J Immunol"},{"key":"2024101711012803000_7.2.00437-2020.47","first-page":"39","article-title":"Eosinophilic airway inflammation in COPD","volume":"1","author":"Saha","year":"2006","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2024101711012803000_7.2.00437-2020.48","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5699(98)01423-6"},{"key":"2024101711012803000_7.2.00437-2020.49","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S152291"},{"key":"2024101711012803000_7.2.00437-2020.50","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.pharmthera.2016.10.016","article-title":"Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation","volume":"169","author":"Nixon","year":"2017","journal-title":"Pharmacol Ther"},{"key":"2024101711012803000_7.2.00437-2020.51","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2008.02958.x"},{"key":"2024101711012803000_7.2.00437-2020.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.04.010"},{"key":"2024101711012803000_7.2.00437-2020.53","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010834.pub3"},{"key":"2024101711012803000_7.2.00437-2020.54","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3300"},{"key":"2024101711012803000_7.2.00437-2020.55","doi-asserted-by":"publisher","DOI":"10.1038\/nri3365"},{"key":"2024101711012803000_7.2.00437-2020.56","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.2147\/COPD.S162781","article-title":"Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease","volume":"14","author":"Mkorombindo","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2024101711012803000_7.2.00437-2020.57","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200912-1843CC"},{"key":"2024101711012803000_7.2.00437-2020.58","first-page":"3","article-title":"Diagnosis, assessment, and phenotyping of COPD: beyond FEV\u2081","volume":"11","author":"Lange","year":"2016","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2024101711012803000_7.2.00437-2020.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2015.08.017"},{"key":"2024101711012803000_7.2.00437-2020.60","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.jaci.2017.11.049","article-title":"Asthma, COPD, and overlap in a national cohort: ACO on a gradient","volume":"141","author":"Bourdin","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"2024101711012803000_7.2.00437-2020.61","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-206740"},{"key":"2024101711012803000_7.2.00437-2020.62","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.150.6.7952628"},{"key":"2024101711012803000_7.2.00437-2020.63","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.06.00072105"},{"key":"2024101711012803000_7.2.00437-2020.64","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00162414"},{"key":"2024101711012803000_7.2.00437-2020.65","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00146306"},{"key":"2024101711012803000_7.2.00437-2020.66","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2213-2600(15)00106-X","article-title":"Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials","volume":"3","author":"Pascoe","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2024101711012803000_7.2.00437-2020.67","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01219-2018"},{"key":"2024101711012803000_7.2.00437-2020.68","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2011.07.002"},{"key":"2024101711012803000_7.2.00437-2020.69","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201509-1869OC"},{"key":"2024101711012803000_7.2.00437-2020.70","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2004.032516"},{"key":"2024101711012803000_7.2.00437-2020.71","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02872-5"},{"key":"2024101711012803000_7.2.00437-2020.72","doi-asserted-by":"crossref","first-page":"962","DOI":"10.3390\/jcm8070962","article-title":"Reassessing the role of eosinophils as a biomarker in chronic obstructive pulmonary disease","volume":"8","author":"Tin\u00e8","year":"2019","journal-title":"J Clin Med"},{"key":"2024101711012803000_7.2.00437-2020.73","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/all.14016","article-title":"Blood eosinophil count and airway epithelial transcriptome relationships in COPD versus asthma","volume":"75","author":"George","year":"2020","journal-title":"Allergy"},{"key":"2024101711012803000_7.2.00437-2020.74","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201408-1458OC"},{"key":"2024101711012803000_7.2.00437-2020.75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cyto.2016.01.007","article-title":"Genetic loci on chromosome 5 are associated with circulating levels of interleukin-5 and eosinophil count in a European population with high risk for cardiovascular disease","volume":"81","author":"McLeod","year":"2016","journal-title":"Cytokine"},{"key":"2024101711012803000_7.2.00437-2020.76","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805435"},{"key":"2024101711012803000_7.2.00437-2020.77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808991"},{"key":"2024101711012803000_7.2.00437-2020.78","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60988-X"},{"key":"2024101711012803000_7.2.00437-2020.79","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290"},{"key":"2024101711012803000_7.2.00437-2020.80","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830190420"},{"key":"2024101711012803000_7.2.00437-2020.81","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.1.9809100"},{"key":"2024101711012803000_7.2.00437-2020.82","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3389\/fphar.2013.00046","article-title":"Eosinophilic inflammation in allergic asthma","volume":"4","author":"Possa","year":"2013","journal-title":"Front Pharmacol"},{"key":"2024101711012803000_7.2.00437-2020.83","first-page":"106","article-title":"Nucala (Mepolizumab): First IL-5 Antagonist Monoclonal Antibody FDA Approved for Maintenance Treatment of Patients with Severe Asthma","volume":"9","author":"Fala","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"2024101711012803000_7.2.00437-2020.84","unstructured":"FDA , Clinical Review - NUCALA (mepolizumab). www.fda.gov\/media\/95114\/download. Date last accessed: 2020; date last updated: 2015."},{"key":"2024101711012803000_7.2.00437-2020.85","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.116576"},{"key":"2024101711012803000_7.2.00437-2020.86","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/11584340-000000000-00000","article-title":"Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody","volume":"50","author":"Smith","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"2024101711012803000_7.2.00437-2020.87","unstructured":"EMA , Nucala: Summary Of Product Characteristics. www.ema.europa.eu\/en\/documents\/product-information\/nucala-epar-product-information_en.pdf. Date last accessed: 2020; date last updated: 2015."},{"key":"2024101711012803000_7.2.00437-2020.88","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2024101711012803000_7.2.00437-2020.89","first-page":"CD010834","article-title":"Mepolizumab versus placebo for asthma","volume":"7","author":"Powell","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2024101711012803000_7.2.00437-2020.90","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02486-2016"},{"key":"2024101711012803000_7.2.00437-2020.91","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.jaci.2018.04.020","article-title":"Biologics and chronic obstructive pulmonary disease","volume":"141","author":"Pavord","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"2024101711012803000_7.2.00437-2020.92","first-page":"681","article-title":"Mepolizumab for eosinophilic COPD","volume":"378","author":"Shahlav-Monavvar","year":"2018","journal-title":"N Engl J Med"},{"key":"2024101711012803000_7.2.00437-2020.93","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1056\/NEJMc1715454","article-title":"Mepolizumab for eosinophilic COPD","volume":"378","author":"Xia","year":"2018","journal-title":"N Engl J Med"},{"key":"2024101711012803000_7.2.00437-2020.94","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708208"},{"key":"2024101711012803000_7.2.00437-2020.95","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13223-019-0348-z","article-title":"Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trial","volume":"15","author":"Ortega","year":"2019","journal-title":"Allergy Asthma Clin Immunol"},{"key":"2024101711012803000_7.2.00437-2020.96","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.11.026"},{"key":"2024101711012803000_7.2.00437-2020.97","first-page":"A4211","article-title":"Outcomes","volume":"201","author":"Moore","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2024101711012803000_7.2.00437-2020.98","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.rmed.2019.07.004","article-title":"Yancey, genetic associations with mepolizumab efficacy in COPD with peripheral blood eosinophilia","volume":"155","author":"Condreay","year":"2019","journal-title":"Respir Med"},{"key":"2024101711012803000_7.2.00437-2020.99","unstructured":"EMA , CINQAERO: Summary Of Product Characteristics. www.ema.europa.eu\/en\/documents\/product-information\/cinqaero-epar-product-information_en.pdf Date last accessed: 2020; date last updated: 2016."},{"key":"2024101711012803000_7.2.00437-2020.100","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200206-525OC"},{"key":"2024101711012803000_7.2.00437-2020.101","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201103-0396OC"},{"key":"2024101711012803000_7.2.00437-2020.102","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2012.642359"},{"key":"2024101711012803000_7.2.00437-2020.103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.04.004"},{"key":"2024101711012803000_7.2.00437-2020.104","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2016.01.003"},{"key":"2024101711012803000_7.2.00437-2020.105","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/JAA.S78049","article-title":"Benralizumab: a unique IL-5 inhibitor for severe asthma","volume":"9","author":"Tan","year":"2016","journal-title":"J Asthma Allergy"},{"key":"2024101711012803000_7.2.00437-2020.106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.05.020"},{"key":"2024101711012803000_7.2.00437-2020.107","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31324-1"},{"key":"2024101711012803000_7.2.00437-2020.108","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31322-8"},{"key":"2024101711012803000_7.2.00437-2020.109","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1080\/02770903.2019.1705333","article-title":"Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma","volume":"58","author":"Bourdin","year":"2021","journal-title":"J Asthma"},{"key":"2024101711012803000_7.2.00437-2020.110","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2213-2600(14)70201-2","article-title":"Benralizumab, an anti-interleukin 5 receptor \u03b1 monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study","volume":"2","author":"Castro","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2024101711012803000_7.2.00437-2020.111","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S2213-2600(14)70187-0","article-title":"Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study","volume":"2","author":"Brightling","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2024101711012803000_7.2.00437-2020.112","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1905248","article-title":"Benralizumab for the Prevention of COPD Exacerbations","volume":"381","author":"Criner","year":"2019","journal-title":"N Engl J Med"},{"key":"2024101711012803000_7.2.00437-2020.113","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S2213-2600(19)30338-8","article-title":"Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies","volume":"8","author":"Criner","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2024101711012803000_7.2.00437-2020.114","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2015.05.018"},{"key":"2024101711012803000_7.2.00437-2020.115","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1365-2222.2009.03383.x","article-title":"Interleukin-13: prospects for new treatments","volume":"40","author":"Brightling","year":"2010","journal-title":"Clin Exp Allergy"},{"key":"2024101711012803000_7.2.00437-2020.116","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2006.01139.x"},{"key":"2024101711012803000_7.2.00437-2020.117","doi-asserted-by":"publisher","DOI":"10.1086\/338242"},{"key":"2024101711012803000_7.2.00437-2020.118","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01387"},{"key":"2024101711012803000_7.2.00437-2020.119","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2217\/imt-2017-0191","article-title":"Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development program","volume":"10","author":"Panettieri","year":"2018","journal-title":"Immunotherapy"},{"key":"2024101711012803000_7.2.00437-2020.120","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2004.04.027"},{"key":"2024101711012803000_7.2.00437-2020.121","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1096\/fj.201801285R","article-title":"IL-13 signaling through IL-13 receptor \u03b12 mediates airway epithelial wound repair","volume":"33","author":"Yang","year":"2019","journal-title":"FASEB J"},{"key":"2024101711012803000_7.2.00437-2020.122","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00422.2009"},{"key":"2024101711012803000_7.2.00437-2020.123","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.1.497"},{"key":"2024101711012803000_7.2.00437-2020.124","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gene.6363896"},{"key":"2024101711012803000_7.2.00437-2020.125","doi-asserted-by":"publisher","DOI":"10.1126\/science.282.5397.2261"},{"key":"2024101711012803000_7.2.00437-2020.126","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2005.02299.x"},{"key":"2024101711012803000_7.2.00437-2020.127","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.2.1021"},{"key":"2024101711012803000_7.2.00437-2020.128","doi-asserted-by":"crossref","first-page":"3140183","DOI":"10.1155\/2019\/3140183","article-title":"ILC2\u2005s induce adaptive Th2-type immunity in acute exacerbation of chronic obstructive pulmonary disease","volume":"2019","author":"Jiang","year":"2019","journal-title":"Mediators Inflamm"},{"key":"2024101711012803000_7.2.00437-2020.129","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.chest.2017.05.019","article-title":"new anti-eosinophil drugs for asthma and COPD: targeting the trait!","volume":"152","author":"Bel","year":"2017","journal-title":"Chest"},{"key":"2024101711012803000_7.2.00437-2020.130","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30307-5"},{"key":"2024101711012803000_7.2.00437-2020.131","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-206719"},{"key":"2024101711012803000_7.2.00437-2020.132","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00223411"},{"key":"2024101711012803000_7.2.00437-2020.133","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2213-2600(18)30184-X","article-title":"Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials","volume":"6","author":"Panettieri","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2024101711012803000_7.2.00437-2020.134","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1080\/13543784.2019.1672657","article-title":"Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma","volume":"28","author":"Marone","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"key":"2024101711012803000_7.2.00437-2020.135","doi-asserted-by":"publisher","DOI":"10.1038\/nrm910"},{"key":"2024101711012803000_7.2.00437-2020.136","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704064"},{"key":"2024101711012803000_7.2.00437-2020.137","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200312-1651OC"},{"key":"2024101711012803000_7.2.00437-2020.138","doi-asserted-by":"publisher","DOI":"10.4137\/CCRPM.S7793"},{"key":"2024101711012803000_7.2.00437-2020.139","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000350852","article-title":"Omalizumab attenuates airway inflammation and interleukin-5 production by mononuclear cells in patients with severe allergic asthma","volume":"161","author":"Takaku","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"key":"2024101711012803000_7.2.00437-2020.140","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.09.035"},{"key":"2024101711012803000_7.2.00437-2020.141","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.11.032"},{"key":"2024101711012803000_7.2.00437-2020.142","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02345-2019"},{"key":"2024101711012803000_7.2.00437-2020.143","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-14-112"},{"key":"2024101711012803000_7.2.00437-2020.144","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1164\/rccm.201912-2384PP","article-title":"Blood eosinophil counts in clinical trials for chronic obstructive pulmonary disease","volume":"202","author":"Singh","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2024101711012803000_7.2.00437-2020.145","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.chest.2017.01.021","article-title":"Hematopoietic processes in eosinophilic asthma","volume":"152","author":"Salter","year":"2017","journal-title":"Chest"},{"key":"2024101711012803000_7.2.00437-2020.146","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1165\/rcmb.2017-0325OC","article-title":"Expression and functional analysis of CST1 in intractable nasal polyps","volume":"59","author":"Kato","year":"2018","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2024101711012803000_7.2.00437-2020.147","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804092"},{"key":"2024101711012803000_7.2.00437-2020.148","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804093"},{"key":"2024101711012803000_7.2.00437-2020.149","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00204-2019"},{"key":"2024101711012803000_7.2.00437-2020.150","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01291-2018"},{"key":"2024101711012803000_7.2.00437-2020.151","doi-asserted-by":"crossref","unstructured":"Higham A , Beech A , Wolosianka S , et al. Type 2 Inflammation in Eosinophilic Chronic Obstructive Pulmonary Disease. Allergy 2020; in press [https:\/\/doi.org\/10.1111\/all.14661].","DOI":"10.1164\/ajrccm-conference.2020.201.1_MeetingAbstracts.A4731"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00437-2020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:05:45Z","timestamp":1740355545000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00437-2020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,14]]},"references-count":151,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,4,12]]},"published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1183\/23120541.00437-2020"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00437-2020","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,14]]}}}